semaj83/ctmatch_classification huggingface dataset:
Patient description: A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Polymyalgia Rheumatica (PMR) Disease Specific Patients must meet the following to be eligible for study entry Diagnosed with polymyalgia rheumatica and enrolled within one month of diagnosis Disease Specific  Patients will be excluded from the study based on the following Symptoms or diagnosis of temporal arteritis, including headache, jaw claudication, hyperesthesia of scalp, abnormal palpated temporal artery, visual disturbances, temporal artery biopsy positivity Concurrent rheumatoid arthritis Presence of rheumatoid factor and CCP Other inflammatory arthritis or other connective tissue diseases, such as but not limited to systemic lupus erythematosus, systemic sclerosis, vasculitis, polymyositis, dermatomyositis, mixed connective tissue disease Treatment of polymyalgia rheumatica with more than 20mg of daily prednisone or its equivalent at the time of screening Treatment with more than 30mg of daily prednisone or its equivalent since diagnosis. Treatment with 30mg of daily prednisone or its equivalent since diagnosis for more than 2 weeks More than 4 weeks of corticosteroid therapy prior to enrollment History of bowel perforation within the past five years Active diverticulitis
Patient description: A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Polymyalgia Rheumatica PMR patients that after 2 years of corticosteroid treatment are not able to reduce the dose of prednisone below 5 mg/day or equivalent PMR patients that after 6 months of corticosteroid treatment are not able to reduce the dose of prednisone below 7,5 mg/day or equivalent PMR patients should fulfill the proposed by Chuang et al (8) Age ≥ of 50 years Development of bilateral moderately/severe aching and stiffness persisting for 1 month or more, involving two of the following areas: neck or torso, shoulders or proximal regions of the arms, and hips or proximal aspects of the thighs ESR ≥ 40 mm/h Complete clinical response to low-dose of steroids (prednisone or equivalent ≤ 20mg/day)  -Patients with biopsy-proven GCA or those with cranial symptoms or signs suggestive of GCA but without biopsy-proven arteritis Patients with clinical features suggestive of RA or other connective tissue disorders Chronic infections such as HIV, hepatitis B or C, active mycobacterial or fungal infections, etc Neoplasm or a history of malignancy in the preceding 5 years Patients with multiple sclerosis or other demilinizating disorders Patients with cytopenias: leukopenia (leukocytes ≤ 3.5x109/L.), thrombocytopenia (platelets ≤ 100x109/L.) and/or anemia (≤ 10 g./dl.) Patients with cardiac failure (functional class III / IV) Any other condition that contraindicates Infliximab therapy
Patient description: A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

Clinical trial eligibility criteria: eligible ages (years): 20.0-89.0,  Allergic Rhinitis Geographic Tongue rhinitis and non-rhinitis patients willing to complete the study no limitation of tongue movement  more than 90 years old or younger than 20 years old unable to complete the study
Patient description: A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Adenocarcinoma Pancreas Histological documentation of primary adenocarcinoma of the pancreas Surgically eligible for tumor resection with curative intent Age> 18 years old ECOG PS 0 or 1 Adequate bone marrow function (WBC>3,000; Hgb>9; Plt>100) Adequate renal function (Cr<1.5ULN) Adequate hepatic function (total bilirubin WNL unless associated with hepatobiliary metastases or Gilbert syndrome, then total bilirubin <2x ULN; and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <2.5 x ULN Signed, written informed consent  Non ductal adenocarcinomas, neuroendocrine neoplasms, cystic tumors of the pancreas such as cystadenomas, cystadenocarcinomas and solid pseudopapillary neoplasms. In addition adenocarcinomas arising from duodenum, distal bile duct, and ampulla will also be excluded Patients with M1 disease Patients with any type of recurrent pancreatic adenocarcinoma Prior therapy such as chemotherapy or radiation therapy for pancreatic cancer Patients with a previous history of active malignancy within 5 years prior to study entry, except 1) in situ cervical carcinoma or 2) non-melanoma skin cancer Previous treatment with any other compound that targets CD40 Concurrent treatment with any anticancer agent outside of this protocol Prior allogeneic bone marrow transplant History of autoimmune disorder, including type 1 diabetes mellitus, pemphigus vulgaris, systemic mastocytosis, systemic lupus erythromatosis, dermatomyositis/polymyositis, rheumatoid arthritis, systemic sclerosis, Sjorgen's syndrome, vasculitis/arteritis, Behcet's syndrome, autoimmune thyroiditis, multiple sclerosis, or uveitis. Vitiligo is allowed History (within the previous year) of stroke or transient ischemic attack, unstable angina, myocardial infarction, congestive heart failure
Patient description: A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Flu Common Cold First Men and women aged 50 + years It is accepted that the subjects can be treated for medical diseases It is also accepted that the subjects receiving daily medication such as diuretics and medication for Hypertension, hypercholesterolemia and blood glucose-lowering treatment, medicine that strengthens the heart, symptom-relieving medication for joint disease, etc Subjects may also use n-3 fatty acids (fish oil), as long as the fixed dosage  Subjects who have been treated with rose hip extracts or powder within 3 months before screening Subjects who have been treated with ginger, avocado / soy, large doses of vitamins (including vitamin C) or other known dietary supplements within 3 months before screening Subjects that have been deemed to be have a hard time collaboration Subjects who abuse narcotics Subjects who abuse alcohol Subjects with a current mental illness Subjects with known allergy to rose hips Subjects participating in another clinical trial, or have participated in another clinical trial within 3 months before this trial started
Patient description: A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

Clinical trial eligibility criteria: eligible ages (years): 5.0-15.0,  Rheumatic Heart Disease Schoolchildren in Southeast Nepal aged 5-15 years Written informed consent by the principal of the school Passive consent from the parents  No formal apply
Patient description: A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Rheumatoid Arthritis The Test Group will be patients with rheumatoid arthritis, newly starting therapy with etanercept (Enbrel). for the exposed cohort subjects are Patients aged 18 years and over at the time of diagnosis Patients from the BSRBR with moderate RA as defined by a DAS28 (>3.2 and ≤5.1) Patients who have given informed consent for long term follow-up and access to all medical records Patients initiating (i.e. at leats one treatment) treatment with etanercept (Enbrel) for RA The Control Group Patients aged 18 years and over a the time of diagnosis Patients from the BSRBR with moderate RA as defined by a DAS28 (>3.2 and ≤5.1) Patients who have given informed consent for long term follow-up and access to all medical records; Patients are receiving at least one traditional DMARD and have never been prescribed a biologic agent  Per BSRBR registry since data is retropsectively being analyzed
Patient description: A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Patient Harboring Glioblastoma That Will Undergo Surgery Patients harboring Glioblastoma Patient will undergo surgery  BMI > 30 Liver and Kidney Function so compromised that medication is prescribed
Patient description: A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Systemic Sclerosis Systemic sclerosis fulfilling ACR or LeRoy's Active polyarthritis defined by > 6/53 tender joints and > 4/53 swollen joints Ongoing first line therapy by prednisone (max 10 mg/d) and (methotrexate, leflunomide, azathioprine or mycophenolate) Birth control if applicable  Overlap syndrome defined by clinical symptoms and positive specific auto-antibodies (anti-CCP, anti-SSA, anti-DNA DNA anti-Sm) (Rheumatoid factors and anti-RNP are not Past therapy with Rituximab Severe and uncontrolled disease with renal, liver or haematological (neutropenia < 1500 / mm3) failures, pulmonary (FVC < 50%) or cardiac insufficiencies (LVEF < 50%) Not stable corticosteroid therapy or cyclophosphamide use in the last 6 months Infectious risk : viral infections by B or C hepatitis or HIV, hypogammaglobulinemia (< 6 G/L), opportunistic infection or infection requiring IV antibiotics in the last 3 months Neoplastic solid tumor in the last 5 years Drug or alcool abuses Receiving patient or having received a biotherapy (anti-TNF, abatacept or tocilizumab) in the last 3 months (possible beyond 3 months)
Patient description: A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Rheumatoid Arthritis A patient will be enrolled in this study if he/she fulfills ALL of the following Male or Female patients ≥ 18 years of age with diagnosis of RA Patient is eligible to start adalimumab therapy according to the local product label and prescription guidelines Patient is naïve to all biologics e.g. anti-cluster of differentiation 4 (anti-CD4) and anti-TNF treatments at the start of the study Patient has no history of inflammatory arthritis other than rheumatoid arthritis Patient has no history of lymphoma or leukemia or other malignancies Has negative result of tuberculosis (TB) screening test or is receiving TB prophylaxis as per local guidelines, Provided written Authorization to the investigator to use and/or disclose personal and/or health data, or Informed Consent if requested by the Local Regulations  Patients that are not diagnosed with rheumatoid arthritis as judged by the American College of Rheumatology Patient is currently diagnosed with any condition other than rheumatoid arthritis that may affect radiography progression Susceptibility to infections including TB, as judged by the investigator Patient is carrier of Hepatitis B virus Patient is a pregnant or lactating female at the time of screening
Patient description: A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Polymyalgia Rheumatica Males or females, 50 years of age or older who provided written informed consent Females less than one year post-menopausal must have a negative serum or urine pregnancy test recorded prior to the first dose of study medication, be non-lactating, and willing to use adequate and highly effective methods of contraception throughout the study. A highly effective method of birth control is defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as sterilisation, implants, injectables, combined oral contraceptives, some IUDs (Intrauterine Device, hormonal), sexual abstinence or vasectomised partner) Subjects newly diagnosed with polymyalgia rheumatica and previously untreated with glucocorticoids for PMR. The diagnosis of polymyalgia rheumatica must be confirmed by all of the following New onset bilateral shoulder pain or new onset bilateral shoulder and hip girdle pain PMR VAS score over the last 24 hours before the Screening Visit ≥ 50 (on a 0 scale) Morning stiffness duration of ≥ 45 min on the day before the Screening Visit Acute phase response shown by elevated C-reactive protein (CRP; ≥ 2 times ULN) Subjects willing and able to participate in all aspects of the study and comply with the use of study medication  Females who are pregnant (positive β-hCG test) or lactating Subjects with any contraindication/history of hypersensitivity to predniso(lo)ne or other ingredients Significant renal impairment (serume creatinine > 150 µmol/L) Significant hepatic impairment (ALT, AST and GGT > 2.5 ULN) Subjects suffering from another disease which requires glucocorticosteroid treatment. Topical glucocorticosteroids, e.g. intra-nasal or inhaled glucocorticosteroids are allowed but should be kept at a stable dose throughout the study Continued use of systemic glucocorticoids within 4 weeks prior to the Screening Visit Joint injections with glucocorticoids within 6 weeks prior to the Screening Visit Subjects who require treatment with non-permitted concomitant therapies Evidence of clinically significant cardiovascular, renal, hepatic, gastrointestinal or psychiatric disease at the time of screening, as determined by medical history, clinical laboratory tests, ECG results, and physical examination, that would place the subject at risk upon exposure to the study medication or that may confound the analysis and/or interpretation of the study results Active alcohol or drug abuse
Patient description: A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis, Polyarthritis Patient 18-75 years of age, inclusive Patient qualifies for primary total knee arthroplasty based on physical exam and medical history, including diagnosis of severe knee pain and disability due to at least one of the following rheumatoid arthritis, osteoarthritis, traumatic arthritis, polyarthritis collagen disorders and/or avascular necrosis of the femoral condyle post-traumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy moderate valgus, varus, or flexion deformities the salvage of previously failed surgical attempts that did not partial or total knee arthroplasty of the ipsilateral knee Patient has participated in a study-related Informed Consent process Patient is willing and able to complete scheduled study procedures and follow-up evaluations Independent of study participation, patient is a candidate for commercially available Persona fixed bearing knee components implanted in accordance with product labeling  Patient is currently participating in any other surgical intervention studies or pain management studies Previous history of infection in the affected joint and/or other local/systemic infection that may affect the prosthetic joint Insufficient bone stock on femoral or tibial surfaces Skeletal immaturity Neuropathic arthropathy Osteoporosis or any loss of musculature or neuromuscular disease that compromises the affected limb Stable, painless arthrodesis in a satisfactory functional position Severe instability secondary to the absence of collateral ligament integrity Rheumatoid arthritis accompanied by an ulcer of the skin or a history of recurrent breakdown of the skin Patient has a known or suspected sensitivity or allergy to one or more of the implant materials
Patient description: A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

Clinical trial eligibility criteria: eligible ages (years): 5.0-17.0,  Acute Rheumatic Fever For the study subjects, diagnosis of ARF was made according to the Modified Jones (4) and appropriate treatment was started. Patients were divided into three groups by clinical findings. Group 1 included patients with only chorea, while patients with arthritis and carditis were involved in Group 2 and patients with only carditis were included in the Group 3. A group with only arthritis was not established since the patients with isolated arthritis are usually followed up at primary and secondary healthcare facilities rather than referring those patients to our tertiary healthcare center
Patient description: A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

Clinical trial eligibility criteria: eligible ages (years): 21.0-99.0,  Joint Pain Breast Cancer Taking an aromatase inhibitor as adjuvant treatment for State I, II, or II breast cancer for at least 4 weeks Experiencing more than mild joint pain/symptoms or older have permission from physician to engage in moderate intensity physical activity  Undergoing chemotherapy and/or radiation therapy at any time during the study period Scheduled for major surgery during the study period Presently engaged in high levels of physical activity on a daily basis Less than 21 years of age Unable to walk or engage in moderate intensity physical activity
Patient description: A 31-year-old woman with no previous medical problems comes to the emergency room with a history of 2 weeks of joint pain and fatigue. Initially she had right ankle swelling and difficulty standing up and walking, all of which resolved after a few days. For the past several days she has had pain, swelling and stiffness in her knees, hips and right elbow. She also reports intermittent fevers ranging from 38.2 to 39.4 degrees Celsius and chest pain.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Degenerative Joint Disease The following diagnostic for patient selection are to be used Patients will need to have a history of chronic pain (at least 3 months) refractory to conservative therapy with non-steroidal anti-inflammatory medications, muscle relaxants, diet modifications and splint therapy Patients will also need to have imaging findings (radiography or magnetic resonance imaging) that show mild to severe degenerative changes of the temporomandibular joint  will Patients with systemic disorders such as rheumatic diseases, hematologic diseases, active infections, immunosuppression Patients receiving therapy with anticoagulants